Abstract:Résumé Les traitements des cancers ont été bouleversés par l'arrivée et le développement des inhibiteurs du check-point (points de contrôle) immunologique (ICI). Ces traitements induisent de multiples effets secondaires dont des insuffisances rénales aiguës. L'association à d'autres traitements rend la réflexion diagnostique complexe. Pour aider les médecins prenant en charge ces patients, la Société française d'immunothérapie du cancer (FITC) et la Société française de néphrologie dialyse et transplantation (SFNDT) proposent des recommandations de prise en charge décrivant le bilan pré-thérapeutique, le diagnostic des différentes atteintes observées et la prise en charge des néphrites interstitielles aiguës secondaires aux ICI. L'essor de l'onconéphrologie, pour laquelle la collaboration entre prescripteurs d'ICI et néphrologues est cruciale, permet d'améliorer les connaissances et l'identification de parcours de prise en charge. Les éléments clés de la réflexion diagnostique sont présentés. La place de la biopsie rénale est revalorisée puisque paraissant peu utilisée par rapport aux bénéfices attendus. Sa réalisation permet de ne pas arrêter à tort l'ICI et d'utiliser les traitements immunosuppresseurs appropriés. Le traitement basé sur la corticothérapie est recommandé selon des schémas dépendant de la sévérité et de la réponse rénale à la corticothérapie. Les traitements alternatifs en cas de résistance à la corticothérapie sont évoqués mais il existe encore peu de données dans les atteintes rénales. La ré-exposition à l'ICI est en général encouragée au vu du faible risque de rechute. Summary Cancer treatments have been dramatically modified by the introduction and the development of immunological checkpoint inhibitors (ICI). These treatments have many side effects, including acute kidney injury (AKI). Their combination with other treatments makes the diagnosis complex. To provide guidance to physicians treating these patients, the FITC and the SFNDT have developed a set of management guidelines covering pre-treatment assessment, diagnosis of the different types of damage observed, and management of acute interstitial nephritis secondary to ICI. Collaboration between oncologists and nephrologists is mandatory. The development of onconephrology is helping to improve knowledge and identify treatment pathways. The key elements of the diagnostic process are presented. The role of renal biopsy is discussed, as it appears to be underused in relation to the expected benefits. Renal biopsy allows ICI to be continued if AKI is not related to AKI. Treatment based on glucocorticoid therapy is recommended, with regimens depending on the severity of the disease and the renal response to glucocorticoid therapy. Alternative treatments for patients resistant to corticosteroids are discussed, but strong data are lacking. Rechallenge should be discussed since it seems to be associated with a good renal prognosis.

Insuffisance rénale aiguë chez les patients traités par inhibiteur du check-point immunitaire-recommandations communes FITC/SFNDT

Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management

The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events

[Management of immunosuppressive therapy after functional renal graft failure: results of a practice survey of French-speaking nephrologists]

Acute interstitial nephritis related to immune checkpoint inhibitors

Immune checkpoint inhibitor-associated nephritis-treatment standard

How To Deal With Renal Toxicities From Immune-Based Combination Treatments In Metastatic Renal Cell Carcinoma. A Nephrological Consultation For Oncologists

Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review

Kidney function while on immune checkpoint inhibitors: Trends in incidence of acute kidney injury, and its causes and outcomes

[Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events].

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

Diagnosis, management, and outcomes of immune checkpoint inhibitor induced acute interstitial nephritis: A single-center experience

Nephrological Detrimental Impacts Resulting From Novel Immunotherapy Drugs Used in the Treatment of Cancer: A Systematic Review

Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience

Immune checkpoint inhibitors and acute kidney injury

The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma

Treatment of acute kidney injury in cancer patients

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis